Safety monitoring of vital signs and cardiovascular effects

The manuals converge on the need for active cardiovascular monitoring during dosing, with repeated attention to blood pressure and heart rate. Across the extracts, the facilitator or therapist is described as tracking vital signs before, during, and after dosing, watching for transient increases or other physiological changes, and remaining alert to symptoms that may signal a safety issue. They also converge on the importance of escalation when changes are clinically significant or exceed expected transient effects. The sources differ in how specifically they frame the cardiovascular effects. The MDMA trial explicitly names expected sympathomimetic effects, including temporary dose-dependent increases in blood pressure and heart rate, plus palpitations, tachycardia, chest discomfort, and vascular symptoms. The 5-MeO-DMT protocol is broader, adding temperature monitoring, triplicate baseline measurements, repeated post-dose checks at specified intervals, and attention to movement during blood pressure readings. The ayahuasca study is more general, noting nonsignificant increases in blood pressure and heart rate and emphasising overall physiological stability, including the possibility of nausea or vomiting without severe compromise.